Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials

Abstract Background Galcanezumab is a novel monoclonal antibody that target to calcitonin gene-related peptide (CGRP). It has been tested for the preventive treatment of migraine and episodic cluster headache by multiple randomized clinical trials (RCTs) and have been found to reduce headache freque...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	The Journal of Headache and Pain
المؤلفون الرئيسيون:	Yanbo Yang, Zilan Wang, Bixi Gao, He Xuan, Yun Zhu, Zhouqing Chen, Zhong Wang
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2020-02-01
الموضوعات:	Migraine Cluster headache Galcanezumab Meta-analysis
الوصول للمادة أونلاين:	https://doi.org/10.1186/s10194-020-1085-x

مواد مشابهة

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
حسب: Angelo Camporeale, وآخرون
منشور في: (2018-11-01)

Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
حسب: Heejung Mo, وآخرون
منشور في: (2022-10-01)

Migren Profilaksisinde Etkili Bir Ajan; Galcanezumab: Tek Merkez Deneyimleri
حسب: Sena Boncuk Ulaş, وآخرون
منشور في: (2024-09-01)

Safety and efficacy of galcanezumab in chronic and episodic migraine patients: a systematic review and meta-analysis of randomized controlled trials
حسب: Mohamed Sayed Zaazouee, وآخرون
منشور في: (2024-05-01)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
حسب: Ivan Urits, وآخرون
منشور في: (2020-10-01)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
حسب: Kenta Kashiwagi, وآخرون
منشور في: (2023-02-01)

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
حسب: Stephen D. Silberstein, وآخرون
منشور في: (2019-06-01)

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
حسب: Simona Guerzoni, وآخرون
منشور في: (2023-06-01)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
حسب: Panagiotis Gklinos, وآخرون
منشور في: (2021-03-01)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
حسب: Mark E. Bangs, وآخرون
منشور في: (2020-01-01)

Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study
حسب: Oralee J. Varnado, وآخرون
منشور في: (2025-04-01)

Cerebral Artery Vasoconstriction After Galcanezumab Loading Dose for Migraine Prevention: A Case Report
حسب: Thanin Asawavichienjinda, وآخرون
منشور في: (2024-10-01)

Cluster headache and galcanezumab: the first real-world Brazilian study and an expert consensus on its use among other treatments
حسب: Abouch Krymchantowski, وآخرون
منشور في: (2024-12-01)

Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
حسب: Stefanie Förderreuther, وآخرون
منشور في: (2018-12-01)

Efficacy of galcanezumab in migraine central sensitization
حسب: Daisuke Danno, وآخرون
منشور في: (2024-09-01)

Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation
حسب: Wanakorn Rattanawong, وآخرون
منشور في: (2025-01-01)

Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
حسب: Hans-Christoph Diener, وآخرون
منشور في: (2025-02-01)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
حسب: Abouch V. Krymchantowski, وآخرون
منشور في: (2023-03-01)

Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine
حسب: Elif Ilgaz Aydinlar, وآخرون
منشور في: (2024-06-01)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
حسب: Tsubasa Takizawa, وآخرون
منشور في: (2022-12-01)

Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
حسب: Keiko Ihara, وآخرون
منشور في: (2023-03-01)

Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
حسب: Marcello Silvestro, وآخرون
منشور في: (2022-06-01)

Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study
حسب: Yooha Hong, وآخرون
منشور في: (2023-10-01)

Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)
حسب: Fabrizio Vernieri, وآخرون
منشور في: (2024-02-01)

Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study
حسب: Samuel Díaz Insa, وآخرون
منشور في: (2024-03-01)

Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
حسب: Mamoru Shibata, وآخرون
منشور في: (2023-09-01)

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
حسب: Marina de Tommaso, وآخرون
منشور في: (2022-04-01)

Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
حسب: Jiying Zhou, وآخرون
منشور في: (2023-08-01)

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry
حسب: Victor Obach, وآخرون
منشور في: (2023-11-01)

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial
حسب: Todd J. Schwedt, وآخرون
منشور في: (2023-11-01)

Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat
حسب: Nadine Friedrich, وآخرون
منشور في: (2024-01-01)

Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
حسب: Takao Takeshima, وآخرون
منشور في: (2024-04-01)

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
حسب: Armin Scheffler, وآخرون
منشور في: (2024-07-01)

Real-life experiences with galcanezumab and predictors for treatment response in Turkey
حسب: Pınar Yalinay Dikmen, وآخرون
منشور في: (2023-11-01)

The impact of remission and coexisting migraine on anxiety and depression in cluster headache
حسب: Byung-Su Kim, وآخرون
منشور في: (2020-05-01)

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
حسب: Licia Grazzi, وآخرون
منشور في: (2024-02-01)

Migraine and cluster headache show impaired neurosteroids patterns
حسب: Angela Koverech, وآخرون
منشور في: (2019-05-01)

Incidence of Migraine Headache
حسب: J Gordon Millichap
منشور في: (1992-10-01)

Migraine and other headaches in transient ischemic attacks
حسب: E. R. Lebedeva, وآخرون
منشور في: (2019-06-01)

Galcanezumab-induced fixed drug eruption
حسب: Skylar Klager, SM, وآخرون
منشور في: (2021-03-01)